Influenza virus conserved antigens (M2e, HA stalk, Nucleoprotein) (M2e-HA-NP)

This target represents a strategic combination of highly conserved influenza virus components: the Matrix 2 protein ectodomain (M2e), the Hemagglutinin (HA) stalk long alpha helix, and the Nucleoprotein (NP). These antigens are the primary focus of universal influenza vaccine research because they exhibit significantly less genetic drift compared to the highly mutable HA head (Erbelding et al., 2018, PubMed: 29554067). M2e is a conserved 24-amino acid peptide that functions as a proton-selective ion channel essential for viral uncoating; the HA stalk mediates the critical membrane fusion step during viral entry; and NP is an internal protein essential for viral RNA packaging and transcription (Schotsaert et al., 2016, PubMed: 26903205). By targeting these regions, therapeutics aim to provide broad-spectrum protection against multiple influenza A and B subtypes, potentially eliminating the need for annual vaccine updates. Current strategies include the development of broadly neutralizing monoclonal antibodies like MEDI8852 and multi-antigen vaccine platforms such as OVX033 or FLU-v that elicit both humoral and cellular immunity (Impagliazzo et al., 2015, PubMed: 26303261). This multi-layered approach is designed to reduce disease severity and prevent viral spread across diverse seasonal and pandemic strains.

Other names

Universal influenza vaccine antigensConserved influenza proteinsM2e-HA stalk-NP complexInfluenza A and B conserved epitopes

Inhibition of the M2 ion channel to prevent viral uncoating; stabilization of the Hemagglutinin (HA) stalk to block the conformational change required for membrane fusion; and induction of cross-reactive T-cell and B-cell immune responses against conserved internal and surface epitopes (Krammer & Palese, 2013, PubMed: 23341456; Wang et al., 2013, PubMed: 23871663).